The Bethesda, Md.-based biotech is no stranger to such preclinical deals, having partnered its early MT203 program with Nycomed A/S in a potential €125 million deal and its D93 antibody with Tracon Pharmaceuticals Inc. for up-front and milestone payments that could top $100 million. (See BioWorld Today, March 19, 2007, and May 25, 2007.) (BioWorld Today) Read More
